Home » ISPOR Posters » Managed Access Agreements: A New Model Pathway For Reimbursement of Non-Oncology Drugs in England Approved Under European Adaptive Pathways?

× Share this Article

Facebook
Twitter
Email
LinkedIn
Google+

Managed Access Agreements: A New Model Pathway For Reimbursement of Non-Oncology Drugs in England Approved Under European Adaptive Pathways?

Share this Article
Facebook
Twitter
Email
LinkedIn
Google+

Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

The Future of UK Drug Pricing: The 2014 PPRS - An Interim Review

Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

The UK Early Access to Medicines Scheme: A 2-Year Status Update On Success, Issues and Controversies

Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

Most Recent Articles

Implications Of Brexit On European Pharmaceutical Market Access

NITAG Hears A WHO!

Orphan Legislation - Left No One Behind?

A Comparison Of Individual Patient Data (IPD) Regression Techniques In Adjusting For Cross-Trial Differences...

Global Growth In Public Healthcare: Emerging Markets Take The Wheel

Biosimilar Market Access: Comparing The US and European Markets

Emerging Privates: Identifying The Major Markets For Private Healthcare Expenditure

A Foot In The Door Or One Foot In The Grave? The Role Of Real World Evidence In Cancer Drugs Fund Re-Appraisals

Squaring The Circle? Using Real World Data From Early Access Programs To Inform Pricing And Reimbursement Decision Making

Nice-ly Paving The Way? Dynamic Pricing: The Future Of Reimbursement

Navigating Real World Evidence In Oncology: Where To Go And Why

Combating Rising Obesity in AMCP Dossiers? The New AMCP Dossier Format - Version 4.0

Commercializing Regenerative Medicines in the US - What Lessons Can We Learn From Europe?

ICER Reports - 4 Years of Cost/QALY Drug Evaluations in the USA...What Does the Future Hold?

Mission Possible? Demonstrating Robust Cost-Effectiveness Without Any Comparative Phase III Data

The Elephant(s) in the Room: Aggrandizement of STA Guidance Workload For Nice

Are FDA Accelerated Approvals Unconditional Approvals?

Is Eunethta Enough? The Remaining Challenges in Navigating the Early European Regulatory and HTA Advice

FDA Orphan Exploitation? Are Pharma's Approaches to Orphan Oncology Drug Approvals Fuelling A Push for Reform by the FDA?

The Future of UK Drug Pricing: The 2014 PPRS - An Interim Review

Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

Return to Home

Welcome to the PAREXEL Access Hub

Managed Access Agreements: A New Model Pathway For Reimbursement of Non-Oncology Drugs in England Approved Under European Adaptive Pathways?

Previous Article

Next Article